Progress of cerebrospinal fluid biomarkers in primary central nervous system lymphoma

VernacularTitle: 原发性中枢神经系统淋巴瘤脑脊液生物标志物研究进展
Author: Jinlong WANG ¹ ; Xudong ZHANG ² ; Qingjiang CHEN ¹ ; Wujun XUE ¹
Author Information

1. Department of Oncology, the Third Clinical College of Xinxiang Medical College, Xinxiang 453000, China
2. Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
Publication Type:Review
Keywords: Central nervous system neoplasms; Lymphoma; Cerebrospinal fluid; Tumor markers, biological; Diagnosis
From: Journal of Leukemia & Lymphoma 2019;28(9):565-568
CountryChina
Language:Chinese
Abstract: Primary central nervous system lymphoma (PCNSL) is one of the subtypes of non-Hodgkin lymphoma, its most pathological type is diffuse large B-cell lymphoma. At present, the gold standard of PCNSL diagnosis is biopsy and pathological examination, but many patients cannot be diagnosed early due to high risk of puncture, patient compliance problems and lack of specific symptoms. PCNSL is sensitive to chemotherapy, but many patients cannot tolerate high-dose chemotherapy or develop drug resistance, leading to disease progression or recurrence. Therefore, the search and identification of biomarkers in cerebrospinal fluid for early diagnosis, efficacy judgment and prognosis monitoring are particularly important for improving the diagnosis and treatment of PCNSL.